![Daphne Karydas](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daphne Karydas
Directeur/Membre du Conseil chez
COMPASS PATHWAYS PLC
Fortune : 159 154 $ au 31/08/2026
Profil
Ms. Daphne Karydas is a President & Chief Financial Officer at Serapha Bio, Inc., an Independent Director at Compass Pathways Plc and an Independent Director at Mineralys Therapeutics, Inc. She is on the Board of Directors at Compass Pathways Plc, Mineralys Therapeutics, Inc. and Epikast, Inc. Ms. Karydas was previously employed as a President & Chief Financial Officer by Flare Therapeutics, Inc., an Independent Director by LogicBio Therapeutics, Inc., a Chief Financial Officer by Syndax Pharmaceuticals, Inc., an Independent Director by Elicio Therapeutics, Inc. (United States), an Independent Director by Eucrates Biomedical Acquisition Corp., a Senior VP-Corporate Financial Planning & Analysis by Allergan Ltd. (Ireland), an Executive Director by JPMorgan Investment Management, Inc., a Vice President by BNY Mellon Investment Adviser, Inc., a Director & Senior Equity Analyst by The Boston Company Asset Management LLC, a Vice President by Goldman Sachs Asset Management LP, an Associate by Goldman Sachs & Co., and a Project Chemical Engineer by Merck & Co., Inc. She received her undergraduate degree from Massachusetts Institute of Technology, a graduate degree from Massachusetts Institute of Technology and an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/09/2026 | 6 200 ( 0,01% ) | 159 154 $ | 31/08/2026 | |
COMPASS PATHWAYS PLC -.--% | 27/05/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Postes actifs de Daphne Karydas
| Sociétés | Poste | Début |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 13/09/2023 |
| COMPASS PATHWAYS PLC | Directeur/Membre du Conseil | 18/09/2023 |
Epikast, Inc.
 Epikast, Inc. Packaged SoftwareTechnology Services Develops AI tools for biopharma and healthcare | Directeur/Membre du Conseil | - |
Anciens postes connus de Daphne Karydas
| Sociétés | Poste | Fin |
|---|---|---|
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of small molecule medicines | President | 08/09/2026 |
| LOGICBIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/11/2022 |
| SYNDAX PHARMACEUTICALS, INC. | Directeur Financier/CFO | 22/10/2021 |
| ALLERGAN PLC | Public Communications Contact | 10/12/2018 |
JPMorgan Investment Management, Inc.
 JPMorgan Investment Management, Inc. Investment ManagersFinance JPMIM seeks to generate positive excess return through both a bottom-up approach emphasizing security selection and a top-down approach focusing on macro investment themes and trends to aid in determining sector weightings, currency, and yield curve weighting where appropriate. The firm offers a broad range of US, non-US and global investment management products and provides different strategies that span the full spectrum of asset classes including equity, fixed-income, cash liquidity, currency, real estate, hedge funds and private equity. | Analyst-Equity | 01/04/2017 |
Formation de Daphne Karydas
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
87
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
The Boston Company Asset Management LLC
 The Boston Company Asset Management LLC Investment ManagersFinance The Boston Company Asset Management (TBCAM) offers both traditional and alternative equity investment products that encompass a variety of US, non-US and global strategies. The firm provides investment advice for the following types of strategies: US domestic equity, balanced, non-US equity, emerging markets equity and long/short equity. Portfolios generally are composed of individual securities. TBCAM seeks consistent delivery of alpha across a broad range of investment strategies. They are committed to a value-oriented, research-driven and risk-aware investment approach. TBCAM seeks to identify attractive stocks through rigorous quantitative and fundamental analyses blended with analysis of current business momentum and places controls on sector selection and, if applicable, country selection. Short sales and similar strategies are considered part of their overall investment strategy; however, they are not used across the account base in the management of account assets. The firm may use these strategies for certain accounts consistent with the client's guidelines, objectives, and restrictions. | Finance |
BNY Mellon Investment Adviser, Inc.
 BNY Mellon Investment Adviser, Inc. Investment ManagersFinance BNYMIA’s investment approach is a team approach where portfolio managers and the research team share information to form a disciplined and consistent strategy that meets the client’s diversification, credit quality, liquidity and average weighted maturity requirements. The firm’s credit research function is fully independent from portfolio management and their dedicated research team employs a deliberately conservative policy, when evaluating individual credits, to help support portfolio credit quality and stability. | Finance |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
JPMorgan Investment Management, Inc.
JPMorgan Investment Management, Inc. Investment ManagersFinance JPMIM seeks to generate positive excess return through both a bottom-up approach emphasizing security selection and a top-down approach focusing on macro investment themes and trends to aid in determining sector weightings, currency, and yield curve weighting where appropriate. The firm offers a broad range of US, non-US and global investment management products and provides different strategies that span the full spectrum of asset classes including equity, fixed-income, cash liquidity, currency, real estate, hedge funds and private equity. | Finance |
Goldman Sachs Asset Management LP
 Goldman Sachs Asset Management LP Investment ManagersFinance GSMALP offers a wide array of investment strategies that span asset classes, industries, and geographies. The firm's products and services across a full range of asset classes including fixed income, money markets, public and private equity, commodities, hedge funds, and real estate. Clients access these solutions through GSAM's proprietary strategies, strategic partnerships, and open architecture programs. | Finance |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Elicio Therapeutics, Inc. (United States)
 Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes pharmaceuticals, devices, biological, surgical & regenerative medicine products | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Compass Pathways Plc
 Compass Pathways Plc BiotechnologyHealth Technology Develops therapies and drugs for the treatment of mental health and neurocognitive conditions | Health Technology |
Eucrates Biomedical Acquisition Corp.
 Eucrates Biomedical Acquisition Corp. Financial ConglomeratesFinance Operates as an blank check company | Finance |
Mineralys Therapeutics, Inc.
 Mineralys Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines to target diseases | Health Technology |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of small molecule medicines | Health Technology |
Epikast, Inc.
Epikast, Inc. Packaged SoftwareTechnology Services Develops AI tools for biopharma and healthcare | Technology Services |
